Phibro Animal Health Corporation (PAHC) Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Consolidated Net Sales: $363.9 million, up 40% year-over-year.

Animal Health Segment Sales: $283.5 million, a 55% increase, driven by:

Medicated Feed Additives (MFA): 81% growth, with $80.5 million from the newly acquired MFA business.

Nutritional Specialties: 13% growth.

Vaccines: 25% growth.

Adjusted EBITDA: $74.9 million, an 85% increase.

Adjusted Net Income: Increased 112%, with adjusted diluted EPS up 108%.

Free Cash Flow: $34 million for the trailing 12 months.

Debt Metrics: Gross leverage ratio at 3.3x, net leverage ratio at 2.9x.

Dividends: Quarterly dividend of $0.12 per share.

2Strategic Updates and Business Highlights

Integration Success: The acquisition of the MFA portfolio is successfully integrated, contributing significantly to sales growth.

Phibro Forward Initiatives: Focus on operational discipline, innovation, and strategic growth, allowing for investments in high-impact opportunities.

New Product Launch: Introduction of Restoris, a dental gel for dogs, aimed at addressing periodontal disease, marking a significant step in the companion animal strategy.

Market Positioning: Strong demand for animal health products is supported by global protein production trends and changing consumer preferences towards high-quality animal-derived proteins.

3Forward Guidance and Outlook

Fiscal Year 2026 Guidance:

Net Sales: $1.425 billion to $1.475 billion (10% to 14% growth).

Adjusted EBITDA: $230 million to $240 million (25% to 30% growth).

Adjusted Net Income: $108 million to $115 million (26% to 34% growth).

Revenue Guidance: No change despite strong Q1 performance, indicating a conservative approach as the company is only one quarter into the fiscal year.

4Challenges and Points of Concern

Performance Products Decline: This segment saw a 7% decrease in sales due to lower demand for personal care ingredients.

Increased SG&A Costs: Higher employee-related costs impacted overall profitability, although mitigated by strong sales growth.

Margin Outlook: While Q1 margins were favorable, a slight decline is expected as the year progresses due to increased investments in new product launches and potential changes in sales mix.

5Notable Q&A Insights

Sustainability of MFA Growth: Management expressed confidence in ongoing demand for MFA products, particularly in poultry and swine, with expectations for continued synergies between legacy and acquired products.

Price vs. Volume Dynamics: Initial MFA growth was primarily volume-driven with limited price impact; future quarters are expected to reflect improved pricing strategies.

Companion Animal Strategy: The licensing of dental assets indicates a strategic focus on the companion animal market, targeting unmet needs rather than competing directly with larger players.

Market Demand Drivers: Strong livestock demand is attributed to global population growth and changing consumer preferences, with Phibro well-positioned to capitalize on these trends. Overall, Phibro Animal Health Corporation reported a robust financial performance in Q1 2026, driven by strategic initiatives and strong market demand, while also addressing challenges in specific segments and maintaining a cautious outlook on revenue guidance.